Board of Directors

Désiré Collen holds an MD degree and a PhD degree in chemistry from the University of Leuven, Belgium, and is founder of ThromboGenics. His team discovered and initially developed tPA, currently the most effective drug for thrombolytic therapy of acute myocardial infarction. He has received 4 honorary doctorates and several scientific awards, including the Francqui Prize (Belgium). Until 2008, he had been director of the Center for Molecular and Vascular Biology of the KULeuven, and the Center for Transgene Technology and Gene Therapy of the Flanders Institute for Biotechnology in Leuven, Belgium. Prof Em Collen is also a nonexecutive director of Beta Cell NV.

Chris Buyse brings to ThromboGenics 20 years of experience in international company finance and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign, where he coordinated its acquisition by BASF in 2007. Before this, Mr Buyse was finance director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and was CFO and interim CEO of Keyware Technologies. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux, and Unilever.

Mr Clay is a Managing Member of East Hill Advisors, LLC, the general partner of East Hill University Spinouts Funds. Prior to cofounding East Hill, he was chairman and CEO of Eaton Vance Corporation, an investment management firm listed on the NYSE. He is chairman of the Clay Mathematics Institute (which he founded in 1998), ADE Corporation, and the Caribbean Conservation Corporation, as well as a director of Golden Queen Mining Co, Ltd. He has served on the boards of the Museum of Fine Arts, Boston; Middlesex School, Concord, Massachusetts; and the Smithsonian Institution, Washington, DC. Mr Clay received an AB, cum laude, from Harvard College and served as an overseer of Harvard from 1975 to 1981. He has donated professorships in mathematics and in scientific archaeology at Harvard and financed Harvard’s share in the construction of the Magellan Telescope in Chile. He has also given smaller observational telescopes to Dexter School and Middlesex School.

Mr Jean-Luc Dehaene has occupied several ministerial posts. He was Prime Minister of Belgium from 1992 until 1999 and vice chairman of the European Convention. He is a member of the board of directors of Umicore NV, Inbev NV, and Lotus Bakeries NV. In October 2008 he was appointed Chairman of Dexia NV/SA. He is also vice president of the King Baudouin Foundation and a member of the European Parliament. Mr Dehaene studied law and economical sciences in Namur and Leuven, Belgium.

Patrik De Haes has more than 20 years of experience in the global healthcare industry, including positions in product development, marketing, and general management. He joined ThromboGenics from Roche, where he was head of their global insulin infusion business. Before that, Dr De Haes was president and CEO of Disetronic Medical Systems Inc, a Minneapolis, Minnestoa-based company specializing in insulin infusion therapy. At Sandoz Pharma (now Novartis), he led the global development and commercialization of the first biotech product for that company. Dr De Haes holds a degree in medicine from the University of Leuven.

Mr Philips earned a degree in commercial and financial sciences and is CFO of KBC Group. In 1997, he was appointed member of the board of directors and the executive committee of Kredietbank NV. From 1998 to 2003, he was managing director of the KBC Bank and Insurance Holding Company and KBC Bank. He was appointed managing director of Almanij in 2003. In the same year, he was also appointed director of the KBC Bank and Insurance Holding Company, KBC Bank, KBC Insurance, and KBL, and became chairman of the audit committee of the first 3 of these companies. After the merger of KBC Bank and Insurance Holding Company and Almanij, Luc Philips remained chairman of the audit committee of KBC Group and KBC Bank, joined the audit committee of KBC Insurance, and became chairman of the board of directors of KBC Insurance and director of KBC Bank and KBC Group. On May 1, 2009, he took up the responsibilities of CFO of KBC Group. Luc Philips is also a member of the board of directors of Norkom Technologies (Ireland) and of Gemma FrisiusFonds (Belgium).

Dr Van Reet is chairman of Movetis NV and managing director of Viziphar Biosciences BVBA, a startup biopharma research and development company, and its subsidiary Viziphar Biosciences PVT Ltd (Bangalore, India), of which he is also chairman of the board of directors. He is also chairman of Okapi Sciences NV and director of the Flanders Institute for Biotechnology (VIB). In 1972 Dr Van Reet joined Janssen Pharmaceutica, an affiliate of Johnson & Johnson, as a member of the group operating committee of the pharmaceutical division, managing director of Janssen Pharmaceutica NV, and Janssen Biotech NV, and chairman of the Janssen Research Foundation. From 2000 until 2004, Dr Van Reet was vice president of Johnson & Johnson Development Corporation, the venturing arm of Johnson & Johnson, and from April until June 2005 he was a member of the management committee of Galapagos NV. Dr Van Reet holds a degree of engineering in applied biological sciences and a PhD in agricultural sciences from the University of Leuven (Belgium) and studied law at the University of Antwerp (Belgium). He is a qualified Belgian and European Patent Authority.

Thomas Clay (26) is Vice-President of East Hill Management Company, a US-based venture capital firm specializing in the lifescience sector. He is also a director of Golden Queen Mining Company Ltd., a development-stage gold mining company, and the Clay Mathematics Institute. Thomas has an AB degree from Harvard University in Classics and a Masters degree from Oxford University in Greek and Latin Languages and Literatures. Thomas replaces his father Landon Clay, who has resigned from the Board.